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Towards 99mTc-based imaging agents with
eﬀective doxorubicin mimetics: a molecular
and cellular study†
S. Imstepf,a V. Pierroz,a,b P. Raposinho,c M. Felber,a T. Fox,a C. Fernandes,c
G. Gasser,a I. R. Santosc and R. Alberto*a
Doxorubicin is a clinical benchmark drug, which is applied in the
treatment of numerous cancers. Known for its accumulation in the
nucleus and ability to intercalate into DNA, it targets quickly divid-
ing i.e. hypermitotic cells. Through this mechanism, it could be an
ideal structural motif for a new class of imaging agents, given that
the new entity approximates the in vitro proﬁle of the parent drug.
Here we describe design, synthesis and biological activity of a
small array of Doxorubicin-metalloconjugates (M = 99mTc, Re). We
demonstrate that the conjugates preferably accumulate in the
nuclear compartment, tightly bind to DNA and retain an appreci-
able cytotoxicity. Moreover, the Re conjugates eﬀectively act as
inhibitors of the human Topoisomerase II enzyme, which is the
widely accepted mechanism of action of the parent drug. Since the
conjugates eﬀectively mimic the in vitro behavior of native Doxo-
rubicin, the 99mTc compounds are prospective imaging agents.
Introduction
Early medical intervention is decisive for the curing of cancer
or prolonging survival.1 For this reason, timely detection of
malignant alterations is crucial. Since macroscopic changes in
cellular structures, i.e. neoplasms, become visible only after
long dwell-times in the body (sometimes years), it is important
to visualize even subtle changes in cellular metabolism early
on. Functional imaging techniques are indispensable to probe
such metabolic changes.2 Single photon emission computed
tomography (SPECT) and positron emission tomography (PET)
are functional imaging techniques, employing radiotracers,
which are routinely used in the clinics. Both modalities rely on
radiation detector devices, which provide external, non-inva-
sive visualization of isotope radiation in the human body. The
specific accumulation, distribution, retention, perfusion and
clearance of the radiotracer provides information on function
and metabolism of the organism.3
An eﬀective imaging agent needs to accumulate in the
target tissue and is retained therein for the time of image
acquisition. Furthermore, the uptake in target versus non-
target tissue should be maximal. One strategy to achieve this
selectivity is the labeling of macromolecules, such as tissue-
specific peptides or antibodies. While labeling of these struc-
tural motifs is attractive because of the inherent targeting
function, costs, issues of in vivo stability, stability under label-
ing conditions and incompatibility of physical half-life and
homing time to the target can be problematic.4 Functional
imaging with small molecules may therefore be favorable, as
prominently exemplified by the majority of small molecule
imaging probes in the clinics. For small molecules, “selective”
accumulation is achieved by the upregulated metabolism of
cancer cells compared to normal cells. This eﬀect enhances
the uptake ratio of a radiotracer in target vs. non-target tissue
and hence allows for visualization and identification of rapidly
dividing cells, as found in malignant tissue alterations.
However, labelling of small molecules can pose significant
challenges. The incorporation of an isotope into a chemical
construct or the appending of a chelated radionuclide e.g. Tc-
99m to a small molecule may significantly alter the delivery,
retention, binding and clearance with respect to the parent
molecule.5 These eﬀects can lead to unwarranted distribution
and pharmacokinetics of the tracer and ultimately to dismissal
of the probe. Nonetheless, chemotherapeutic agents are ideal
structural motifs to guide radiotracers into target tissue and
eﬀect accumulation therein, given that the radiotracer closely
mimics the parent drug in vivo.
Doxorubicin (ADR) is a natural, broadband chemotherapeu-
tic agent, which is known to intercalate strongly between DNA
nucleobases.6–8 ADR is clinically well-proven and shows exten-
sive activity against a variety of cancers.9–11 Its mode of action
is commonly ascribed to the inhibition of Topoisomerase II
and to the resulting damage during DNA replication, inducing
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apoptosis, the programmed cell death pathway.12 Since DNA is
the primary target of ADR, it could well serve as a lead struc-
ture for a novel class of radiotracers intended to image hyper-
mitotic tissue. Additionally, Elsinga et al. have shown that
anthracycline-based radiotracers can be employed to probe
P-glycoprotein (Pgp) in vivo in view of assessing if tumors are
subject to multidrug resistance (MDR).13 Overexpression of
Pgp in resistant tumors leads to an enhanced drug eﬄux and
hence reduced eﬀective drug concentration in tumor cells.
This is typically associated with a poor therapy response to
anthracycline-based chemotherapy agents, such as ADR.
Neoadjuvant imaging with anthracycline-based radiotracers
has therefore been proposed as a prognostic factor for therapy
outcome and an indication for combined treatment with Pgp-
modulators (e.g. verapamil,14 cyclosporine A 15) during chemo-
therapy, in order to enhance the tumor response to anthra-
cycline drugs. If successful this strategy would follow a
“theranostic” approach: neoadjuvant imaging with an anthra-
cycline-based imaging agent and follow-up treatment with the
unmodified parent drug.
Inspired by ADR’s clinical relevance and the wide-spread
availability of 99mTc for nuclear medical applications we set
out to synthesize a small array of ADR-99mTc(CO)3 bioconju-
gates. We have previously reported on the first ADR-metallo-
conjugates (1,2 see Scheme 1) and observed that these
derivatives eﬃciently targeted the cell’s nucleus or mitochon-
dria.16,17 In this study we expand this series with structurally
diﬀering ADR metalloconjugates (3–6), which were closely
examined with regard to their capabilities of mimicking the
parent drug in vitro. The “cold” Re-conjugates were scrutinized
for binding aﬃnity to DNA, inhibition of human Topoisomer-
ase II and in vitro cytotoxicity since Re organometallic com-
plexes were found in recent years to have an interesting
cytotoxic profile.18 Studies on the cellular localization of the
metalloconjugates were carried out by confocal fluorescence
microscopy to assess their ability to target the cell’s nucleus
and the in vitro distribution was corroborated by two indepen-
dent quantification modalities. In addition, we present a new
key intermediate for C14-derivatives of ADR, which allows for
easily accessible derivatives of the parent drug, while the integ-
rity of the daunosamine sugar moiety is conserved.
Results & discussion
Design and synthesis of the ADR-conjugates
All synthetic data can be found in the ESI, Charts S1–S24.† Bio-
conjugates 3–6 (Scheme 1) were designed according to the
bifunctional chelator (BFC) concept:19 The biological vector
(ADR) is conjugated via a carbon linker to the chelator, which
binds strongly to the fac-[M(CO)3]
+ core (M = Re/99mTc). ADR is
an autonomous nuclear targeting moiety for rapidly dividing
cells and designated to ferry the pendant (radio-)metal into
the nucleus, where intercalation into the DNA guarantees for
retention. Unlike the previously reported ADR-complexes (1,2),
conjugates 3 and 4 were designed with a free amine group on
the α-carbon to enhance the conjugate’s hydrophilicity and to
mimic the underivatized daunosamine-NH2-group of the of
the parent drug, which is known to be a critical point of inter-
action with DNA (Scheme 2).20
The Fmoc-C1 fragment was synthesized according to
Zubieta and coworkers.21 The dipicolyl (DPA) chelator was
introduced by direct reductive amination of commercially
available Fmoc-Lys-OH with an excess of picolinaldehyde and
sodium triacetoxyborohydride (STAB) as the reducing agent
(Scheme 2). This chelator moiety was then reacted with the
standard precursor (NEt4)2[ReBr3(CO)3] in a microwave to yield
Fmoc-Re-C1. During this reaction we observed the formation
of a side product, attributable to the corresponding methyl-
ester.22 It likely forms due to activation of the free acid by the
Lewis acidic fac-[Re(CO)3]
+-fragment when methanol is the
solvent. Formation of this side product, however, can be con-
trolled by minimizing the reaction time and the excess of Re
precursor. As the methyl ester is not very prone to amide for-
Scheme 1 ADR-based metalloconjugates as imaging probes: previously reported complexes 1 (M = 99mTc) and 2 (M = Re) and new bioconjugates
3–6.
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mation, this species was not of concern and the crude reaction
mixture was thus directly used in the following step. Reaction
of commercially available ADR·HCl with either Fmoc-C1 or
Fmoc-Re-C1, in a HBTU mediated amide bond formation,
yielded the respective Fmoc protected ADR derivatives, which
were deprotected in the last step using piperidine in DMF.
After purification by preparative HPLC bifunctional chelator
L1 and Re-complex 4 were obtained in yields of 21% (3 steps)
and 20% (4 steps), respectively. Both species were fully charac-
terized by detailed NMR studies (see ESI, Charts S4–S6 and
S10–S12†).
Conjugates 5 and 6 (Scheme 3) were designed according to
a diﬀerent concept. As evident from crystal structures, the
daunosamine glycoside binds to the minor groove of DNA.23
While the artificially introduced, free NH2-group in 3 and 4
may enhance the integrity of the ADR–DNA interaction, block-
ing of the glycosidic amine still likely disrupts the natural
binding mode of ADR to DNA. In contrast, the hydroxyl group,
located on C14, clearly points away from the double helix
during intercalation. L2 was designed to maximize the binding
capability of the conjugates to DNA and was hence derivatized
with a chelator on C14. HS-DAP contains the 2,3-diaminopro-
pionic acid (DAP) moiety – an excellent chelator for the fac-
[M(CO)3]
+-core (M = Re, 99mTc) – and its synthesis was described
by Felber et al.24 The polyethylene glycol linker was chosen for
solubility reasons and its well tolerated biocompatibility.
Reaction of N-protected ADR with an excess of mesylchlor-
ide (MsCl) in dry CH2Cl2 aﬀorded the C14-mesylate Fmoc-
ADR-OMs which, to the best of our knowledge, is a new key
intermediate for ADR derivatives. Under carefully controlled
conditions, the C14–OH reacts rather selectively with MsCl, as
it is the only primary hydroxyl and the most nucleophilic
Scheme 2 Synthesis of ADR conjugates 3 and 4. (i) 2-Pyridinecarboxaldehyde, STAB, DCE 25 °C, 62%; (ii) (NBu4)2[ReBr3(CO)3], MeOH, microwave,
110 °C, 84% (iii) ADR·HCl, HBTU, DIPEA, DMF, 25 °C, Fmoc-L1: 56%, Fmoc-4: 68% (iv) 10% piperidine in DMF, 25 °C, L1(·2TFA): 62%, 4(·2TFA): 58% (v)
[99mTc(OH2)3(CO)3]
+, H2O, 60 °C, 64% radiochemical yield (RCY). STAB = sodium triacetoxyborohydride, DCE = 1,2-dichloroethane, DIPEA = N,N-
diisopropylethylamine, HBTU = N,N,N’,N’-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexaﬂuorophosphate, DMF = N,N-dimethylformamide,
MeOH = methanol.
Scheme 3 Synthesis of ADR-conjugates 5 and 6. (i) MsCl, TEA, CH2Cl2, 0–25 °C,72%, (ii) K2CO3, DMF, 25 °C, 62%, (iii) 10% Piperidine in DMF, 25 °C,
54%, (iv) 5: [99mTc(OH2)3(CO)3]
+, H2O, 60 °C, 78% RCY, 6: (NBu4)2[ReBr3(CO)3], DIPEA, H2O, 25 °C, 55%. MsCl = methanesulfonyl chloride, TEA = tri-
ethylamine, DMF = N,N-dimethylformamide, DIPEA = N,N-diisopropylethylamine.
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alcohol of ADR. Fmoc-ADR-OMs can be obtained in good to
excellent yields, ready for the following step or for storage after
preparative HPLC purification. Even though a C14 bromide of
Daunorubicin has been published by Israel et al.,25 literature
is void of a method to convert ADR directly into a strong elec-
trophile. The mesylate obtained in this new way is easily dis-
placed by nucleophiles, under mild conditions, and may
alleviate laborious synthetic procedures to access C14 deriva-
tives of ADR, such as the clinically applied Valrubicin
(Valstar™), the C14-valerate ester of ADR.26,27
The soft thiol nucleophile in HS-DAP eﬃciently displaced
the mesylate in a SN2 reaction from Fmoc-ADR-OMs under
conditions adapted from Seshadri et al.28 After cleavage of the
Fmoc group with piperidine in DMF and HPLC purification L2
was obtained in 24% overall yield (3 steps). Reacting L2 with
(NEt4)2[ReBr3(CO)3] and HPLC purification aﬀorded ADR-con-
jugate 6 in 55% yield. Chelator L2 and Re-complex 6 have been
fully characterized by NMR (see ESI, Charts S16–S18 and S22–
S24†). We note that L2 and 6 form a mixture of diastereomers
by coupling racemic HS-DAP to enantiomerically pure ADR.
No attempts were undertaken to separate the diastereomers,
as neither the passive uptake of ADR nor intercalation into
DNA requires stereochemically pure substances. Table 1 sum-
marizes the synthesized ADR-conjugates and the relative
hydrophilicities, reflected in the partition coeﬃcients between
n-octanol and PBS buﬀer (logDO/PBS).
99mTc radiolabeling
For the labeling of chelators L1 and L2, [99mTc(OH2)3(CO)3]
+
was prepared according to a modified procedure.30,31 The
three labile water ligands in this 99mTc precursor are displaced
by the strong chelators DPA (L1) and DAP (L2) to yield excellent
radiolabeling eﬃciencies of up to 95%. RP-HPLC purification
of the crude solutions aﬀorded ADR-99mTc conjugates 3 and 5
in good radiochemical yields (RCY) of 64% and 78% respec-
tively. However, labeling conditions needed to be mild and
carefully controlled. We observed a general trade-oﬀ between
labeling at lower pHs (4–5), which kept the protonated chela-
tors L1 and L2 in solution, but reduced the radiolabeling
eﬃciency due to unavailability of free electron pairs on proto-
nated nitrogens. Additionally, lower pHs promoted α-glycosidic
cleavage. Vice versa, at pH values exceeding 6–7 the labeling
eﬃciency was markedly enhanced but now, the neutral, hydro-
phobic chelators precipitated from the aqueous solution.
Labeling experiments carried out in methanol were in support
of the observed pH dependencies, as in this solvent byproduct
formation was almost completely suppressed. The optimal
conditions for fully aqueous labeling of ADR-chelates were T =
55–60 °C for 30 min, after careful quenching of the kit-con-
tained boranocarbonate and readjusting the pH to 6–7. Since
co-injection with the “cold” rhenium homologue is the
accepted procedure for authentication of new 99mTc radio-
products at the tracer level, Fig. 1 shows HPLC chromatograms
of the purified ADR-conjugates 3 and 5 and the respective co-
injections with Re-complexes 4 and 6. For the in vitro experi-
ments, 3 and 5 were purified by HPLC to radiochemical
purities (RCP) ≥95% (see ESI, Chart S25†).
Cytotoxicity studies
ADR is a strongly cytostatic agent with excellent inhibitory
potencies against various cancer cell lines. It was hence of inter-
est to assess if the new ADR-bioconjugates retained this cyto-
toxicity. The activity of conjugates 4 and 6 against the human
cervix carcinoma (HeLa) cell line was studied by the fluoro-
Table 1 ADR-conjugates and partition coeﬃcients between n-octanol
and phosphate buﬀer in comparison to native ADRa
Compound Chelator position logDO/PBS
ADR29 n/a 0.45 ± 0.03
1/216 Daunosamine 0.92 ± 0.03
3/4 Daunosamine 0.71 ± 0.04
5/6 C14 0.75 ± 0.02
a Values indicate means ± standard deviations of five measurements.
Fig. 1 Normalized HPLC co-injections. Top left: γ-trace of 3 (17.48 min, RCP >95%), bottom left: UV-trace of rhenium complex 4 (17.25 min); top
right: γ-trace of 5 (17.78 min, RCP >98%), bottom right: UV-trace of rhenium complex 6 (17.66 min). Diﬀerences in retention time result from a serial
detector setup. RCP = radiochemical purity.
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metric Resazurin cell viability assay.32 For comparison pur-
poses, cisplatin was used in the same assay as internal refer-
ence. As shown in Table 2, bioconjugates 4 and 6 exhibited
appreciable toxicities after 48 h of incubation. Like conjugate
2, these derivatives exhibit IC50 values which approximate the
one of cisplatin, yet, the activities are markedly reduced with
respect to native ADR. Still, conjugates 4 and 6 showed some-
what lower IC50 values than 2, likely owed to the more rationale
design of the new bioconjugates: the artificially introduced
amine group in 4 and the underivatized daunosamine in 6
aﬀorded ADR derivatives which draw closer to the parent ADR,
both in terms of hydrophilicity (see Table 1) and the possibility
to bind DNA through hydrogen bonds rather than an electro-
static interaction via the charged metal center. It is evident
that metalloconjugates of ADR could exhibit potentially useful
cytotoxicity profiles after careful optimization of the pendant
complexes. Such bioconjugates could yield new metallo-drugs
that follow a diﬀerent mechanism of action and possibly over-
come the acquired MDR, observed for the parent drug.
DNA binding aﬃnity
Nuclear DNA is the primary target of ADR and anthracene
glycosides are known to strongly intercalate into DNA. This
durable interaction with DNA is the cause of manifold toxic
actions such as inhibition of DNA biosynthesis,33–35 DNA
crosslinking,36,37 interference with DNA unwinding,38 strand
separation and helicase activity.39,40 Ideally, an eﬀective ADR
mimic should thus target nuclear DNA and the aﬃnity of con-
jugates 4 and 6 for DNA was evaluated in this respect. The
binding aﬃnity of ADR derivatives is frequently studied by
means of their auto-fluorescence, which is quenched in the
presence of increasing amounts of double stranded calf-
thymus DNA (ctDNA). Fitting this titration data to the non-
cooperative model for DNA binding28,29 allows for determi-
nation of the binding constant (Kb) and the size of the inter-
action site (s), which are reported in Table 3. As observed for
native ADR, the initial fluorescence of the bioconjugates is
maximal in the absence of ctDNA (see ESI, Chart 26†). In all
instances it was strongly quenched at increasing DNA concen-
trations but no shift in the emission maximum (593 nm) was
observed. Fig. 2 exemplarily shows the emission data and
binding curves for ADR in the presence of ctDNA. All ADR
derivatives showed a reduced aﬃnity to ctDNA compared to
the parent drug; we previously attributed this phenomenon to
derivatization at the glycoside’s amine.16 Conjugate 4, which
comprises an additional amino group, exhibited a comparable
binding aﬃnity as native ADR. Apparently, the introduction of
this free NH2-group strengthens the binding to DNA – possibly
via the formation of hydrogen bonds to DNA – as this intro-
duced amine is the only structural diﬀerence compared to
derivative 2. On the contrary, the Kb of conjugate 6 is markedly
lower than those of ADR and 4, even though this construct
comprises an unaltered daunosamine moiety. We hypothesize
that the lengthy linker and the bulky Re-complex impede an
eﬀective intercalation. Nevertheless, the binding constants
obtained for the examined ADR bioconjugates indicate strong
aﬃnities for DNA. Even at the tracer level (99mTc concen-
trations: <µM), the great majority of all molecules are bound to
DNA, theoretically enabling an eﬀective retention of the radio-
tracers in the cell’s nuclei.
Inhibition of human Topoisomerase II
Despite the ubiquitous clinical use of ADR, its cytotoxic
action is still under debate. Apart from interference with DNA
Table 2 Inhibitory potency (IC50) values for conjugates 2, 4, 6 and for
ADR incubated with HeLa cellsa
Compound Cell line
HeLa (µM)
Cisplatin 9.6 ± 1.1
ADR 0.093 ± 0.02
2 19.7 ± 2.1
4 6.2 ± 2.3
6 12.2 ± 2.4
a Cisplatin was used as internal reference. Values indicate means ±
standard deviations of three independent experiments.
Table 3 Parameters extracted from the ctDNA titration of ADR and
derivativesa
Compound (µM) Kb (M
−1 per nucl) × 106 s (bp)
ADR (2.8) 4.98 ± 0.45 2.00 ± 0.04
2 (6.5) 0.23 ± 0.03 2.20 ± 0.15
4 (0.68) 4.11 ± 0.29 0.29 ± 0.01
6 (3.8) 0.63 ± 0.11 1.26± 0.12
a Kb: aﬃnity constant, s: binding site size.
Fig. 2 Binding curve of ADR (2.8 µM) to DNA. Symbols indicate Fbound
calculated by equation (2, ESI†) and the dashed line represents the non
linear squares ﬁt to the non-cooperative binding model. Inset: emission
spectra (510–700 nm) of ADR in PBS buﬀer. Note that the initial ﬂuor-
escence is quenched upon increasing the concentration of ctDNA
(arrow).
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biosynthesis (vide supra) diﬀerent mechanisms have been pro-
posed in literature. Yet it is accepted that ADR is a strong
inhibitor of human topoisomerase II (hTopoII).41 We showed
previously that ADR conjugate 2 eﬀectively inhibited human
hTopoII α and β, which was an incentive to look for a possible
correlation between the strong binding to DNA, the toxicity of
ADR conjugates 4 and 6 and inhibitory activity towards
hTopoII α and β. We employed a method of Shapiro et al.42,43
which exploits the preferred binding of the fluorescently
labeled (TTC)3T oligonucleotide to double-stranded plasmid
DNA, containing a triplex forming sequence, after relaxation
by hTopoII α or β versus the supercoiled plasmid.39,40 Changes
in fluorescence anisotropy were monitored at increasing
inhibitor concentrations to calculate the %-inhibition and the
IC50 was determined by nonlinear least-squares fit of the data
points to an adaptation of the Hill equation. The concen-
tration dependent inhibition of hTopoII α and β by complexes
4 and 6 and fitting of the data to the Hill equation can be
found in the ESI, Chart 28.† Table 4 indicates that Re com-
plexes 4 as well as 6 eﬀectively inhibited the activity of hTopoII
α and β at similar concentrations as reported for native ADR.
The similar structures of conjugates 2 and 4 can be directly
compared and it is evident that the enhanced ability of 4 to
inhibit hTopoII α and β is consistent with the above-shown
superior IC50 and stronger binding to DNA. No correlation
between toxicity in HeLa cells and hTopoII inhibition can be
found for 6: it outperforms all presented inhibitors in this
assay, but is less toxic than 4 and ADR. This absence of a one-
to-one relationship between Topoisomerase inhibition and
cytotoxicity is reminiscent of the above-mentioned multiple
modes of action of ADR. Nonetheless, it is remarkable that the
structural changes of ADR, by derivatizations at diﬀerent posi-
tions with metal complexes, do not impede the inhibition of
hTopoII α and β. We note that in addition to retaining toxicity
and DNA binding, the novel ADR bioconjugates mimic also
this feature of the parent drug.
Cellular localization and distribution
The red autofluorescence of the anthraquinone chromophore
(λabs = 488 nm, λem = 592 nm) allows for cellular localization of
ADR derivatives by confocal microscopy. Fig. 3 displays the
fluorescence distribution of conjugates 4 (20 µM) and 6
(20 µM) compared to native ADR (1 µM), after 2 h of incu-
bation in HeLa cells. Both derivatives showed an eﬃcient cellu-
lar uptake, as cytosolic fluorescence was detected already at
10 min post incubation. After the full 2 h period, complex 4
exhibited a predominantly cytoplasmic and enhanced peri-
nuclear staining. Although we observed some fluorescence in
the nucleus, it was diminishingly weak, yet somewhat stronger
in nucleolar regions. We note that by closer examination the
fluorescence distribution of 4 resembles a negative image of
the parent ADR and that comparable fluorescent staining
observations were made for 2.16 In contrast, conjugate 6 exhibi-
ted a diﬀerent picture: while a fluorescence signal was
observed both in the cytosol and nucleus, the nuclear lumine-
scence was now clearly enhanced and the nucleoli stained to a
reduced extent, much like the parent drug.
When examining the fluorescence distribution of ADR
derivatives, caution is advised due to altering fluorescence fea-
tures which strongly depend on their immediate environ-
ment.44 For example, complex 2 showed a nucleus void of
fluorescence, but revealed a predominant accumulation in the
nuclear compartment after quantifications of the metal
content.16 Thus, we directly proceeded with quantifying the
sub-cellular distribution of conjugates 3–6 in order to make a
firm assessment.
The presence of 99mTc (conjugate 3 and 5) and Re
(conjugates 4 and 6) in homologous compounds allows for
very sensitive quantification of metal contents in cellular
Table 4 Potencies (IC50s) of hTopoII α and β inhibitors as determined in
the ﬂuorescence anisotropy-based assaya
Enzyme
Inhibitor hTopoII α (µM) hTopoII β (µM)
ADR42 1.6 ± 0.2 1.1 ± 0.02
2 9.4 ± 1.2 4.5 ± 0.6
4 3.3 ± 0.7 2.4 ± 0.5
6 0.90 ± 0.08 1.0 ± 0.1
a Values indicate means ± standard deviations of three replicate
measurements made for the two enzymes in parallel.
Fig. 3 Confocal ﬂuorescence microscopy of native ADR (1 µM) and Re
conjugates 4 (20 µM) and 6 (20 µM) in HeLa cells after 2 h incubation.
Left: red autoﬂuorescence (excitation at 488 nm, emission above
600 nm), center: DAPI nuclear stain, right: merge of autoﬂuorescence
and DAPI staining. DAPI = 4’,6-diamidin-2-phenylindol.
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compartments. 99mTc can be quantified by direct measurement
of the decay-corrected activity and the Re content by induc-
tively-coupled mass spectrometry (ICP-MS). Consequently,
HeLa cells were incubated with either purified radioconjugates
(3/5) or Re conjugates (4/6) for 2 h. Post incubation cells were
washed with buﬀer to remove unbound metal and nuclei and
mitochondria were isolated from whole cells by a modified
procedure for mitochondria extraction from cultured cells. At
this point the metal content in the nucleus and mitochondria
pellets was determined by a dose calibrator or ICP-MS, after
chemical digestion in aqua regia, and was expressed relative
(%) to the content in the whole cell pellet. Fig. 4 and Table 5
summarize the results. Evidently, all ADR conjugates 3–6
target the nucleus as the great majority (70–80%) of metal
content was recovered from this organelle, whereas 2–3% of
the compounds accumulate in mitochondria. Furthermore,
the compiled data showed no significant diﬀerences in relative
uptake values between the examined compounds and quantifi-
cation modalities. Since the quantification results of ADR con-
jugate 4 and 6 are in excellent agreement with those previously
reported for complex 2, it must be concluded that a lacking
nuclear fluorescence is observed due to a reduced overall
uptake of the metal conjugates compared to native ADR and
nearly complete quenching upon intercalation into nuclear
DNA. The appearance of in vitro fluorescence from ADR deriva-
tives is highly concentration dependent and thus ill-suited as a
standalone tool for an unambiguous determination of the cel-
lular localization.
In terms of absolute uptake values (see Table 5), the cellu-
lar accumulation of conjugates 5 and 6 is greater compared
to bioconjugates 3 and 4. We attribute these diﬀerences to
the higher lipophilicity of 5 and 6, as lipophilic ADR deriva-
tives are known to enhance the cellular uptake.45 Interest-
ingly, we found that conjugate 5 and 6 show a twofold greater
absolute uptake compared to 3 and 4. According to ICP-MS,
the calculated concentration of 6 in the cell nucleus is
roughly 140 µM, a value which markedly exceeds the one of 4
(65 µM) and previously 2 (33 µM). Moreover, it draws much
closer to the nuclear concentration of native ADR, which
can reach up to 340 µM at saturation.46 The enhanced
nuclear concentration of 6 is well in line with the observed
excess luminescence signal, as seen in confocal microscopy
(vide supra).
Summary and conclusion
Doxorubicin (ADR) is a widely applied chemotherapeutic
agent. Because of its ability to target hypermitotic tissue, it
could serve as a structural motif for new imaging agents and/
or a molecular imaging probe for multidrug resistance.
In this work we studied four new ADR bioconjugates (3–6)
with regard to their ability to mimic native ADR. The cold
rhenium surrogates 4 and 6 were shown to be cytotoxic and to
strongly bind to DNA. Moreover, the scrutinized compounds
are capable of eﬀectively inhibiting the nuclear human Topo-
ismorease II enzyme at concentrations well comparable to native
ADR. Cellular localization and uptake were studied by confocal
microscopy and corroborated with two independent quantifi-
cation modalities. Compared to the parent drug, the rhenium
derivatives 4 and 6 are taken up to a reduced extent but still
eﬀectively target the nucleus. Especially conjugate 6 seems to
be an attractive candidate for further evaluation, as its nuclear
uptake is clearly articulated in comparison to 2 and 4. Overall,
the presented data evidences that Re-conjugates 4 and 6, as
well as 99mTc-conjugates 3 and 5 are excellent mimics of native
ADR in vitro, despite substantial structural deviations from the
natural molecule. Indeed, they have a prospect as imaging
agents. In vivo evaluations are currently ongoing to study their
biodistribution. Furthermore, the 99mTc bioconjugates are
Fig. 4 Relative Re (ICP-MS) and 99mTc (dose calibrator) uptake in the diﬀerent cellular compartments of HeLa cells treated for 2 h with 20 µM of 4
and 6 or ∼12 MBq of 3 and 5.
Table 5 Quantiﬁed uptake into cells and subcellular compartments in
HeLa cells for 4, 6 (M = 185Re) and 3, 5 (M = 99mTc)a
Conjugate 4 6
185Re [ng/106 cells] [ng/106 cells]
Whole cell 13.38 ± 1.41 24.37 ± 0.75
Nucleus 10.28 ± 0.71 (76.8%) 21.99 ± 2.05 (80.34%)
Mitochondria 0.29 ± 0.13 (2.1%) 1.27 ± 0.03 (5.2%)
Conjugate 3 5
99mTc [kBq/106 cells] [kBq/106 cells]
Whole cell 19.92 ± 0.88 45.49 ± 0.64
Nucleus 16.01 ± 0.57 (80.4%) 36.25 ± 2.02 (79.7%)
Mitochondria 0.41 ± 0.04 (2.06%) 1.73 ± 0.12 (3.80%)
a Rhenium was quantified by ICP-MS (20 µM, n = 3). 99mTc was
quantified in a dose calibrator (∼12 MBq, n = 3). Incubation time was
2 h. Values represent means ± standard deviations per 106 cells. Values
in brackets are relative to the whole cell fraction.
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subject of experiments in ADR resistant and sensitive cells to
determine their potential as in vivo probes for P-glycoprotein.
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